Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
On the broadcast Geert said something like the data will be ready in maybe two months or four months...he really doesn’t know
The makers of car grills are no longer able to afford palladium and will replacing it with a nickel composite in the laboratory. This means in eight years it will turn to rust and you’ll have to replace your grill.
https://docs.google.com/spreadsheets/d/1d-TsBuhUZ8_yhcNGTHxOd3-ydAXQsQbD_y_F_wNhv8A
The above is from March 2017
Eat dates for potassium. I love them so much.
Regarding the video, in Japan, we’d say, “I’m going to soapland.”
This is the reply I got when I asked a student what he would do if he only had 24 hours to live. He got a big laugh.
Sorry were you talking about APTO?
You can contact him directly. His email was posted here last week. I’m sure he stands by his $37 prediction.
On Thu, Dec 5, 2019 at 13:29 vidpok450 <vidpok450@aol.com> wrote:
(Xxxxxx,) very happy for you and your family. This stock should end a lot higher after the buyout.
Best regards, Dave
Either way, he must have a turd in his pocket
That makes it unanimous.
800% is enough for me
Thank you for the video link. What a horrible disease (9:40~) and totally under-reported considering no data from China, India, or Africa.
Look who slithered back.
“May have to re-access...”
Are you trying to say ‘reassess’?
I never click links that don’t have any description about what the link is all about
I'm in at $2.40 and $3.70. Selling in 2-3 years.
After Kramer it rocketed up to about 7.70 I believe then returned to what it was pre-Creamer
$37, not $80 was his estimate.
I use them to explain to my spouse why I'm doing this investment. They're pretty persuasive.
Adam Feuerstein @adamfeuerstein
·
1h
Personal news: I am leaving TheStreet. I accepted an offer to join STAT as senior writer and National Biotech Columnist. @statnews
Thank you very much
Dead link.
Not necessarily. Scientologists are into money more than anything else
1. Performed > competition 2. Prevents infections (HUGE ++) 3. Widely applicable. 4. CHEAPER
Trading in and out of a stock can also be considered bad advice. Short term capital gains tax will kill my profits. Personally, I prefer to be patient.
2012 article on how the pigs, I mean the bears, hold down stock prices.
https://seekingalpha.com/instablog/2918951-g-hudson/1026551-how-the-big-players-manipulate-the-stock-market
It was also wise to take the money ($23.75) in January rather than wait till February for $24. It's funny in hindsight.
Thank you for the spreadsheet. Makes it so much easier to explain to the family.
After the dilution it settled and then it started to rise again quickly, from high sevens to low nines. This 4% drop can be attributed to the healthcare bill fiasco. Are you new here? Welcome.
Sold. Lost $769. Had been up $15,000. Was bragging to my wife.
He said he only holds Aurinia now. I had ARRY but sold it for $1200 profit
Cerulean will announce it.
Would be the quickest BO for me. I've waited as long as four years for ARIAD (150%) and SQNM (to lose money!) and about a year for YMI (30%), but I have only been in CERU (130%) for three weeks. Will definitely be the most profitable.
Denner felt the same way.
I'm hoping for a 20 bagger. Hold.
If you have a high risk tolerance invest before the data. If not you can wait until after the data is released, according to the DD.
I'm kind of an ignoramus but I think it means due diligence. Looks like somebody posted some homework
Looks like it's going right back to $10 in the after hours
Ok, I'll stick with it. Thanks for the info.
Oil prices are going to go down. I would short this.
I criticized Ariad Pharmaceuticals (ARIA) for jacking up the price of Iclusig and questioned the sanity of those who believe the lung cancer drug brigatinib is anything more than a me-too late comer. Still, Ariad's share price almost doubled in value in 2016, mainly on takeout speculation. Ouch! My grade: Incomplete (because I still don't believe Ariad will be acquired.)
- Adam Feuerstein, Dec. 22, 2016